Healthcare provider profile · identity verified

Peter J Kim, MD

Internal Medicine · LOS ANGELES, CA · NPI 1235242199

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	787	269
Losartan Potassium	Losartan Potassium	335	103
Amlodipine Besylate	Amlodipine Besylate	309	91
Omeprazole	Omeprazole	247	100
Levothyroxine Sodium	Levothyroxine Sodium	241	64
Metformin Hcl	Metformin Hcl	233	75
Gabapentin	Gabapentin	213	92
Naproxen	Naproxen	213	153
Azithromycin	Azithromycin	203	165
Creon	Lipase/Protease/Amylase	173	68
Vascepa	Icosapent Ethyl	154	40
Tramadol Hcl	Tramadol Hcl	144	71
Rosuvastatin Calcium	Rosuvastatin Calcium	131	47
Alendronate Sodium	Alendronate Sodium	125	52
Tamsulosin Hcl	Tamsulosin Hcl	122	43
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	120	44
Amoxicillin	Amoxicillin	112	87
Hydrochlorothiazide	Hydrochlorothiazide	105	34
Fluticasone Propionate	Fluticasone Propionate	93	57
Famotidine	Famotidine	91	39
Celecoxib	Celecoxib	87	40
Metoprolol Succinate	Metoprolol Succinate	87	31
Trazodone Hcl	Trazodone Hcl	84	47
Farxiga	Dapagliflozin Propanediol	83	16
Temazepam	Temazepam	81	36
Meloxicam	Meloxicam	78	36
Prednisone	Prednisone	74	34
Methotrexate	Methotrexate Sodium	73	21
Myrbetriq	Mirabegron	66	20
Glipizide	Glipizide	65	22
Clotrimazole	Clotrimazole	58	40
Diclofenac Sodium	Diclofenac Sodium	58	33
Lidocaine	Lidocaine	58	19
Clopidogrel	Clopidogrel Bisulfate	57	18
Zolpidem Tartrate	Zolpidem Tartrate	56	20
Pregabalin	Pregabalin	51	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	50	39
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	49	44
Mupirocin	Mupirocin	47	38
Sertraline Hcl	Sertraline Hcl	47	12
Donepezil Hcl	Donepezil Hcl	46	19
Montelukast Sodium	Montelukast Sodium	46	suppressed
Icosapent Ethyl	Icosapent Ethyl	45	17
Alprazolam	Alprazolam	44	23
Linzess	Linaclotide	44	13
Finasteride	Finasteride	43	15
Paxlovid	Nirmatrelvir/Ritonavir	43	43
Januvia	Sitagliptin Phosphate	42	15
Simvastatin	Simvastatin	39	17
Olmesartan Medoxomil	Olmesartan Medoxomil	36	suppressed
Raloxifene Hcl	Raloxifene Hcl	36	11
Jardiance	Empagliflozin	35	suppressed
Prolia	Denosumab	35	24
Albuterol Sulfate Hfa	Albuterol Sulfate	33	19
Azelastine Hcl	Azelastine Hcl	33	suppressed
Humira(Cf) Pen	Adalimumab	33	suppressed
Loperamide	Loperamide Hcl	30	28
Sildenafil Citrate	Sildenafil Citrate	30	suppressed
Carvedilol	Carvedilol	27	suppressed
Entecavir	Entecavir	26	suppressed
Acyclovir	Acyclovir	25	11
Breo Ellipta	Fluticasone/Vilanterol	25	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	25	11
Furosemide	Furosemide	24	13
Clonazepam	Clonazepam	23	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	23	suppressed
Glipizide Er	Glipizide	23	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	22	11
Lisinopril	Lisinopril	22	suppressed
Meclizine Hcl	Meclizine Hcl	21	12
Shingrix	Varicella-Zoster Ge/As01b/Pf	21	16
Tradjenta	Linagliptin	21	suppressed
Allopurinol	Allopurinol	20	suppressed
Cephalexin	Cephalexin	19	14
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	13
Megestrol Acetate	Megestrol Acetate	19	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	19	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Ciclopirox	Ciclopirox	18	suppressed
Dextrose In Lactated Ringers	Dextrose 5%-Lactated Ringers	18	15
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Solifenacin Succinate	Solifenacin Succinate	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Nystatin	Nystatin	17	14
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	17
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	16	suppressed
Ozempic	Semaglutide	16	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	13
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Trulicity	Dulaglutide	15	suppressed
Ursodiol	Ursodiol	15	suppressed
Zenpep	Lipase/Protease/Amylase	15	suppressed
Atenolol	Atenolol	14	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Evenity (2 Syringes)	Romosozumab-Aqqg	13	suppressed
Folic Acid	Folic Acid	13	suppressed
Humira(Cf)	Adalimumab	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Paxlovid (Eua)	Nirmatrelvir/Ritonavir	13	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Valsartan	Valsartan	13	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Jentadueto	Linagliptin/Metformin Hcl	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Forteo	Teriparatide	11	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Memantine Hcl Er	Memantine Hcl	11	suppressed
Simponi	Golimumab	11	suppressed
Xeljanz	Tofacitinib Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error